A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
Inclusion Criteria:
Are willing to follow contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
If assigned female at birth, pre-/peri- and postmenopausal status is allowed. Those with pre- or peri-menopausal status at study entry must agree to use ovarian function suppression with any locally approved gonadotropin-releasing hormone (GnRH) agonist.
If assigned male at birth with an estrogen receptor positive (ER+) breast cancer diagnosis, they must agree to use hormone suppression with a GnRH agonist.
Have histologically or cytologically confirmed breast cancer, defined as individuals with
locally advanced breast cancer not amenable to curative therapy (for example, surgery) or metastatic disease, and
hormone receptors (HR)+/human epidermal growth factor receptor 2 (HER2)- or HR+/HER low defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines
Have evidence of an activating PIK3CA mutation, detected in tumor or blood samples using an appropriate assay.
Have measurable disease or non-measurable, evaluable bone disease
Part 1:
Part 2:
Received 0 prior systemic treatment for advanced breast cancer not amenable to curative therapy (for example, surgery) or metastatic disease.
Individuals who are eligible are either
Population 1 (P1): Endocrine sensitive
Population 2 (P2): Endocrine resistant
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Anchorage, Alaska 99508, United States
907-257-9851
Tucson, Arizona 85719, United States
Irvine, California 92612, United States
Irvine, California 92618, United States
Los Angeles, California 90033, United States
Orange, California 92868, United States
Grand Junction, Colorado 81501, United States
Greeley, Colorado 80631, United States
Loveland, Colorado 80538, United States
Washington D.C., District of Columbia 20010, United States
Miami, Florida 33136, United States
Tampa, Florida 33612, United States
Newnan, Georgia 30265, United States
Worcester, Massachusetts 01655, United States
Minneapolis, Minnesota 55407, United States
Saint Louis Park, Minnesota 55426, United States
Tupelo, Mississippi 38801, United States
Cary, North Carolina 27518, United States
Chapel Hill, North Carolina 27599, United States
Columbus, Ohio 43210, United States
Lancaster, Pennsylvania 17601, United States
Philadelphia, Pennsylvania 19104, United States
Philadelphia, Pennsylvania 19107, United States
Charleston, South Carolina 29425, United States
Houston, Texas 77030-4009, United States
Burlington, Vermont 05401, United States
Fortaleza, 60430235, Brazil
Rio de Janeiro, 22250-905, Brazil
São Paulo, 01317-000, Brazil
Fuzhou Fujian, 350001, China
Wuhan, 430022, China
Zhanjiang, 524002, China
Vandœuvre-lès-Nancy, 54519, France
Friedrichshafen, 88045, Germany
Athens, 151 23, Greece
Bologna, 40138, Italy
Meldola, 47014, Italy
Kahoku-gun, 920-0293, Japan
81120023812
Otashi, 373-8550, Japan
81120023812
Cheonan-si, 31151, South Korea
82-10-2529-3895
Deagu, 41404, South Korea
+82 53 200 3011
Gangnam-gu, 06273, South Korea
020193305
Hospitalet, 08907, Spain
+34932607283
Salamanca, 37007, Spain
Adana, 01250, Turkey (Türkiye)
Ankara, 06200, Turkey (Türkiye)
Ankara, 06620, Turkey (Türkiye)
480-301-8000
501-624-7700
479-872-8130
714-456-8614
323-397-5954
707-651-5213
714-456-8614
760-416-4749
707-651-5213
310-998-4747
707-651-2797
707-651-2797
970-493-6337
970-298-7500
970-810-3894
970-810-3894
352-242-1366
239-264-7026
904-953-2000
386-774-1223
478-336-5708
912-692-2000
912-651-5771
808-432-8000
217-545-8000
319-353-6665
301-571-2016
617-632-3800
508-856-3216
612-863-8716
507-284-2511
651-254-3572
816-932-2677
417-882-4880
646-888-5157
919-350-2873
919-260-4616
330-888-4000
330-492-3345
330-888-4000
614-366-1525
330-888-4000
843-792-9300
615-341-4383
325-670-7724
833-832-8328
214-648-4180
214-648-4180
832-728-7423
713-600-0900
281-944-3610
425-690-3503
920-364-3600
5491150523121
5491133147765
5491163819972
1130051657
5411 70781548
93516778868
341-5717551
542644211086
549-264-4826407
03364456047
61 7 3176 2111
0293555652
0361666655
0424579224
+61 3 5832 2322
61744331111
3225413188
+3211337979
3256633900
003216345129
003281720524
003210437648
3237602975
551733216637
+55 (98) 991187100
55433792608
+55 84 4009 5595
555133203039
+5511956598420
551138933525
5511983366440
551123598425
55 11 4450-0300
416 946 4534
86 13811012595
18981838521
13960709993
18933183766
0574-87085588
13601637369
33490276397
33370632403
0659321781
467926155
+33172389434
+33172389434
33240679977
0531155127
4920411061601
004922147837567
00493405014310
49990629993911
00493514586728
4921144773360
+4991318533572
+4920117433005
00496995332228
004927030020
0049551488795915
4968411628101
+493419723400
004971419990
00496131170
004989440077581
+4933124135643
00493681355016
0049611432377
004923021733290
0492028961411
306946462998
30 2103381547
2106185202
302106185177
302105831265
2810-392750
302413502785
302610999791
306974000528
306947330432
012214000
014103000
3538092010
390105558904
0039 347 488 6271
00390257489215
390392339037
+390817463660
3908117770442
0039 0498 215931
393393018718
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
6564368000
82-10-9314-1980
1047617651
82220720795
82222288135
82230103217
+34924218040
34935460139
+34 93 274 60 00
34927621612
0034943328400
958840490
953220306
641971167
973003754
+34913368263
34913303000 ext 7768
34913908626
94951032508
34 871 206 130
922677351
981950511
651056277
34961973583
34 976 76 57 46
886-42359-2525-5031
886-6-2353535 x4620
886228712121
02289700111686
905353067506
90538 609 92 02
00903125957321
00905053170639
905326845953
+905323860161
+90 532 590 70 57
905324510608
01316518709
02078828494